Vaccine Storage and Handling are critical aspects of the vaccine supply chain, ensuring that vaccines remain safe, effective, and potent from the time they are manufactured until they are administered to individuals. Proper storage and handling procedures are essential to maintain the stability and integrity of vaccines and prevent their degradation or spoilage. Vaccines are sensitive biological products that can lose their potency if exposed to inappropriate storage conditions, such as extreme temperatures, light, or improper handling. Therefore, vaccines must be stored and transported within a specific temperature range recommended by the manufacturer, typically between 2°C and 8°C (36°F to 46°F) for most vaccines.
Specialized vaccine storage units, such as refrigerators and freezers, are used to maintain the recommended temperature range and protect vaccines from temperature fluctuations. These units should be equipped with temperature monitoring devices, such as digital data loggers or thermometers, to continuously monitor and record the temperature to ensure compliance with storage requirements. Vaccine storage units should also be properly organized to prevent overcrowding and ensure adequate air circulation around the vaccines. During transport, vaccines should be packed in insulated containers with temperature-monitoring devices to maintain the recommended temperature range. Cold chain management practices, such as using cold packs or ice packs, are employed to keep vaccines within the appropriate temperature range during transit. Proper vaccine handling procedures are also essential to prevent contamination and maintain vaccine integrity. Healthcare providers should adhere to strict hygiene practices, such as handwashing and wearing gloves, when handling vaccines to minimize the risk of contamination.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States